Make way for virtual screening

Virtual screening is being hailed by some as a superior method of evaluating compounds compared to high throughput screening. However, it’s still important to choose wisely between a ligand- or protein-based model template, as both are prone to mishandling.

In the June issue of Innovations in Pharmaceutical Technology, Cresset’s Tim Cheeseright and Rob Scoffin discuss virtual screening as a proven technology that can replace large-scale HTS runs in order to create a more focused data set for a smaller-scale screen.

Read the article in IPT, pages 16 to 19.